News & Views - Page 43 of 53 - Telix Pharmaceuticals Limited

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field of urologic oncology.

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer imaging product.

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton, UK

Telix Granted TGA Priority Review for Prostate Cancer Imaging

Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography (PET).

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Telix Pharmaceuticals announces it has entered into a licensing and partnership agreement with DuChemBio

Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product

Telix has been granted HREC approval and received CTN clearance by the TGA to commence Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients with advanced prostate cancer.

Investor Briefing – TheraPharm GmbH Acquisition

Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition.

Investor Conference Call: Telix’s acquisition of TheraPharm GmbH

Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm GmbH.

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH

Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)